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CLINICAL CHARACTERISTICS OF FAMILIAL GENERALIZED 
ANXIETY DISORDER 
Kenneth S. Kendler, Michael C. Neale, Ronald C. Kessler, Andrew C. Heath, 
and Lindon J. Eaves 
The authors seek to determine whether the clinical characteristics of general- 
ized anxiety disorder (GAD) darer in individuals with a high us. low familial 
vulnerability to illness. We identified 486 personally interviewed female twins 
from a population-based register who had both a n  interviewed co-twin and a 
lifetime histo y of GAD using modified DSM-III-R criteria which required a 
one-month minimum duration of illness. We attempted to predict risk f o r  
GAD in the co-twinfiom the clinicalfeatures of the GAD in the proband twin 
using the Cox proportional hazard model, controlling f o r  year of birth and 
zygosity. Only two variables uniquely predicted an  increased risk f o r  GAD in 
the co-twin: number of G A D  symptoms endorsed and comorbidity with 
bulimia. Variables that did not uniquely predict risk of illness in the co-twin 
included age a t  onset, duration of the longest episode and number of episodes. 
The familial vulnerability to GAD can be mean in f i l l y  indexed by clinical 
features of the syndrome. These results suggest that i f t he  syndrome of GAD is 
to be narrowed, it would, Porn a familial perspective, be more valid to increase 
the minimum number of required symptoms rather than to increase the mini- 
mum duration of illness. Anxiety 1:186-191 (19941199s). o 199s mky-~ks, Inc. 
Key words: anxiety, family studies, generalized anxiety disorder, comorbidity, 
twin studies 
INTRODUCTION 
Although generalized anxiety disorder (GAD) was 
formally proposed as a diagnostic category less than 20 
years ago (Spitzer et al., 1975; Brown et al., 1994), the 
criteria for this disorder have, during this period, been 
revised many times. The minimum duration of illness 
has variously been set at two weeks (Spitzer et al., 
1979, one month (American Psychiatric Association, 
1980) or six months (American Psychiatric Associa- 
tion, 1987). The minimum number of required symp- 
toms has varied from one out of five (Spitzer et al., 
1975), a t  least one from three of four groups (Ameri- 
can Psychiatric Association, 1980), six out of eighteen 
(American Psychiatric Association, 1987) and most re- 
cently, to three out of six (American Psychiatric As- 
sociation, 1994). Various diagnostic hierarchies have 
also been applied to GAD, ranging from excluding 
GAD syndromes when they are “due to” another 
mental disorder (American Psychiatric Association, 
1980) or excluding cases which meet criteria only 
during episodes of psychotic or mood disorders 
(American Psychiatric Association, 1987, 1994) or 
only when also meeting criteria for a psychotic dis- 
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order, a mood disorder, Briquet’s syndrome or panic 
disorder (Spitzer et al., 1975). 
Although concern has been expressed about the va- 
lidity of GAD as a diagnostic category (Barlow et al., 
1986; Breslau et al., 1987; Breier et al., 1985; Brown et 
al., 1994), few studies have explicitly attempted to vali- 
date diagnostic criteria for this disorder. Breslau and 
Davis (1985), for example, found that a six-month 
minimum duration of illness may more confound than 
improve the descriptive validity of GAD. 
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Familial aggregation remains one of the most im- 
portant validating criteria for psychiatric disorders 
(Robins and Guze, 1970). In this report, we examine 
results from a population-based study of female twins 
to determine the clinical characteristics of GAD that 
predict familial aggregation. 
METHODS 
SAMPLE 
Characteristics of this sample have been outlined 
previously (Kendler et al., 1992a). In brief, this sample 
of Caucasian female same-sex twins, born from 1934 
to 1971, was obtained from the population-based Vir- 
ginia Twin Registry, formed from a systematic review 
of birth records in the Commonwealth of Virginia 
from 1915 onward. Twins were eligible to participate 
if both members of the pair responded to a mailed 
questionnaire, the response rate to which was approxi- 
mately 64%. Of the 2,352 individuals from 1,176 twin 
pairs who met these criteria, we succeeded in personally 
interviewing 2,163 (92.0%) of them, including both 
members of 1,033 pairs. Of the completed interviews, 
89.3% were performed face to face and 10.7% by tele- 
phone. No difference was found in the rate of GAD in 
those assessed by these two methods. The mean age (k 
S.D.) of the sample at  interview was 30.1 * 7.6. Zygosity 
was determined by the use of standard self-report ques- 
tions, photographs, and when uncertain, genotyping by 
DNA polymorphisms. Final zygosity diagnoses yielded 
590 MZ, 440 DZ and 3 pairs of unknown zygosity. 
MEASURES, INTERVIEWERS AND 
DIAGNOSTIC REVIEW 
A lifetime diagnosis of GAD was made using an ad- 
aptation of an early version of the Structured Clinical 
Interview for DSM-111-R Diagnosis (SCID; Sp’ itzer et 
al., 1987), a reliable instrument for the diagnosis of 
GAD (Rislund et al., 1987). This adaptation differed 
from current versions of the SCID in three significant 
ways. First, the introductory question was modified to 
inquire about periods of at least one rather than six 
months in duration. Second, no question inquired 
whether the anxiety or worry affected two or more life 
circumstances. Third, the SCID item inquiring about 
one of the 18 symptomatic criteria for GAD (#11, 
“flushes or chills”) was inadvertently left off the inter- 
view, reducing the total number of symptomatic crite- 
ria from 18 to 17. 
The lifetime diagnosis of GAD was based on a blind 
review by K.S.K., an experienced psychiatric diagnos- 
tician, using DSM-111-R criteria (American Psychiatric 
Association, 1987), except that the required minimum 
duration of illness was reduced from six months to one 
month and issues of diagnostic hierarchy were ig- 
nored. GAD was not diagnosed when the symptoms 
were considered due to medical illness or medication. 
In addition, lifetime diagnoses were made using DSM- 
111-R criteria for panic disorder, major depression, al- 
cohol dependence, anorexia nervosa and bulimia 
nervosa. With two exceptions, we applied, for these 
diagnostic categories, unmodified DSM-111-R criteria. 
For bulimia, we included “subsyndromal” bulimic-like 
syndromes because in this sample they closely re- 
sembled, from both an epidemiologic and a genetic 
perspective, those cases meeting full DSM-111-R crite- 
ria (Kendler et al., 1991). Phobia was defined as the 
presence of one or more irrational fears that objec- 
tively interfered in the respondent5 life. Based on the 
approach used by Leckman et al. (1983) in a study of 
major depression, probands with GAD with a lifetime 
diagnosis of major depression or panic disorder are di- 
vided into those where the disorders were always asso- 
ciated with GAD episodes (here termed contemporaneom 
comorbid cases) and those that were, at least some of 
the time, separate from the GAD episodes (here 
termed non-contemporaneom comorbid cases). 
All interviewers, who underwent extensive and on- 
going training during the field study, had a minimum 
of either a Master’s degree in Psychology or Social 
Work or a Bachelor’s degree and at least two years 
clinical experience. The  same interviewer never inter- 
viewed both members of a twin pair. 
If a twin answered positively to the “stem” question 
for GAD on the SCID, and answered positively to at 
least five of the symptomatic criteria, then she was 
asked three additional questions about her episodes of 
GAD including: (1) age a t  first episode, (2) total num- 
ber of episodes, and (3) length of longest episode. 
Inter-rater reliability was assessed in 53 jointly con- 
ducted interviews. Each of these interviews was blindly 
reviewed and the percent agreement and chance cor- 
rected agreement (Cohen, 1960) for the diagnosis of 
GAD was 91% and + 0.77 * 0.10 @ < O.OOl), respectively. 
TREATMENT OF INDIVIDUAL SYMPTOMS 
While it would be of interest to determine the rela- 
tionship between each individual symptom and risk for 
GAD in the co-twin, the performance of 17 separate 
tests would introduce an unacceptably high probabil- 
ity of a spurious positive finding. Therefore, for the 
purpose of data reduction, we submitted a product- 
moment correlation matrix for all 17 symptoms to a 
factor analysis and VARIMAX rotation (SAS Institute, 
1985; results available on request). Three factors were 
identified and (along with the items with the heaviest 
loading, all positive), in descending order, were as fol- 
lows: autonomic hyperactivity (shortness of breath, 
palpitations, dizziness, feeling shaky and sweating), 
hypervigilance (trouble concentrating, trouble sleeping, 
exaggerated startle, irritability, muscle tension and keyed 
up) and gastrointestinal symptoms (dry mouth, fre- 
quent urination, restlessness, upset stomach and lump 
in throat). “Easy fatigability” did not load distinctly on 
any three of these factors. Similar factors were ob- 
tained if the factor analysis was conducted using 
tetrachoric correlations. Factor scores for these three 
factors were used in subsequent analyses. 
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STATISTICAL ANALYSIS 
Since our goal was to examine the relationship be- 
tween clinical characteristics of GAD in affected twins 
and the risk for GAD in their co-twins, our analysis 
focused on pairs of observations: a proband twin with 
GAD and her co-twin. Twin pairs where neither had a 
lifetime diagnosis of GAD were, per force, excluded 
from the analysis. The  remaining pairs could be di- 
vided into two groups: (1) pairs where only one twin 
had GAD, which are “counted” once in our analysis, 
and (2) pairs where both twins had GAD, which are 
“counted” twice in our analysis. 
Since GAD has an age-dependent onset and our 
sample is variable with respect to age, we utilized the 
Cox proportional hazard model, as operationalized in 
the PHGLM procedure in SAS (SAS Institute, 1986). 
In the Cox model, the dependent variable is the haz- 
ard rate for GAD, defined as the risk for a previously 
unaffected twin to develop GAD in a given unit of 
time, here a year. A twin with no lifetime diagnosis of 
GAD is retained in the analysis until her current age, 
at which point she is “censored” (i.e., removed) from 
the analysis. 
Although “double” counting twins from concordant 
pairs does not result in a bias in parameter estimation 
(McGue et al., 1984), some correction is required for 
incorrectly assuming the independence of the observa- 
tions from these doubly counted twin pairs (n = 83). If 
T is the total number of observations, N the number 
of doubly counted twin pairs, and P the number of 
parameters in our model, we multiplied the stan- 
dard errors obtained by [(T-P)/(T-N-P)]”. Although 
approximate, this correction is likely to be conserva- 
tive (IGsh and Frankel, 1974). All significances re- 
ported are based on our corrected standard errors. In 
the stepwise proportional hazard model, we used entry 
and exit criteria of 0.50 and 0.10, respectively. For all 
analyses, we utilized the traditional p 2 .05 criterion 
for significance. All xz analyses from the Cox analyses 
have one degree of freedom. 
We wanted in all our analyses to control for two 
variables: zygosity and year of birth. Zygosity was in- 
cluded to control for the higher risk observed in MZ 
vs. D Z  co-twins of affected twins (Kendler et al., 
1992a). Year of birth was included to control for any 
possible cohort effect for GAD. Probandwise concor- 
dance, tetrachoric correlations and biometrical model 
fitting for GAD in this sample have been reported 
previously (Kendler et al., 1992b). 
RESULTS 
CHARACTERISTICS OF THE SAMPLE 
Key clinical characteristics of 
the 486 twins with GAD, who had a mean age (k S.D.) 
at interview of 28.7 * 9.0, are seen in Table 1. This 
sample had a mean and median number of episodes of 
4.2 and 2, respectively. The mean and median dura- 
Clinical Features. 
TABLE 1. Clinical features of GAD in the proband 
twin that predict risk for GAD in the co-twin“ 
Variable Mean * S.D. x2 P 
Age at onset 22.5 * 8.5 0.00 0.957 
Number of 9.3 * 2.9 18.58 0.000 
Maximum duration 29.4 2 78.9 0.02 0.886 
symptomatic criteria 
(weeks) 
Number of episodes 4.2 * 9.8 5.20 0.022 
“Controlling for zygosity and year of birth. 
tion of the longest episode of illness was 29.4 and 9 
weeks, respectively. The  mean and median number of 
total endorsed symptoms was 9.3 and 9, respectively. 
Comorbidity. The  proportion of twins meeting 
criteria for GAD who also made criteria for a lifetime 
diagnosis of the other assessed psychiatric disorders is 
seen in Table 2 and ranged from 1.6% for anorexia 
nervosa to 48.5% for phobia. The  proportion of twins 
with GAD who met criteria for major depression and 
panic disorder only during episodes of GAD was 23.7 
and 3.3%, respectively. 
PREDICTION OF RISK FOR GAD 
ONE AT A TIME 
Clinical Features. The relationship between the 
clinical characteristics of GAD in the proband and the 
risk for GAD in the co-twin, as assessed by the Cox 
Proportional Hazard model, controlling for zygosity 
and year of birth, is presented in Table 1. Both the 
number of endorsed symptomatic criteria and the total 
number of episodes significantly predicted an in- 
creased risk for GAD in the co-twin (p = 0.000 and 
0.022, respectively). However, neither age a t  onset of 
GAD nor maximum duration of an episode bore any 
relationship to the risk for GAD in the co-twin. 
The  impact of comorbidity, taken 
one disorder at a time, on the risk for GAD in the co- 
twin is seen in Table 2. While the co-occurrence in the 
proband twin of any disorder increased the risk for 
IN THE CO-TWIN: VARIABLES TAKEN 
Comorbidity. 
TABLE 2. Comorbidity as a predictor of risk for GAD 
in the co-twin’ 
Disorder Kind Frequency (%) 
Major depression NCb 45.1 
Panic disorder NC 13.0 
Panic disorder C 3 . 3  
Phobia L T ~  48.5 
Alcohol dependence LT 12.8 
Bulimia LT 9.7 
Anorexia LT 1.6 










“Controlling fir  zygosity and year of birth. 
‘NC, nonontemporaneous; C, contempormeous; L7; lifetime. 
Research Article: Familial Generalized Anxiety Disorder 189 
GAD in the co-twin, this effect was statistically signifi- 
cant only for non-contemporaneous panic disorder 
and bulimia (p = 0.029 and 0.039, respectively). 
Controlling for zygosity and year of 
birth, autonomic hyperactivity (xz = 4.66, p = 0.03 l), 
and hypervigilance (x’ = 9.72, p = 0.002) significantly 
and positively related to the risk of GAD in the co- 
twin, while the results for gastrointestinal symptoms 
were nearly significant (x’ = 3.54, p = 0.060). Since to- 
tal number of endorsed symptoms was strongly related 
to risk for GAD in the co-twin, we repeated the analy- 
sis of the symptom factors, controlling for the total 
number of endorsed symptoms. In these analyses, 
none of the symptom factors any longer significantly 
predicted risk of GAD in the co-twin: autonomic h - 
peractivity (xz = 1.09, p = 0.297), hypervigilance (x = 
1.00, p = 0.3 17) and gastrointestinal symptoms (x’ = 
PREDICTION OF RISK FOR GAD IN THE 
Symptoms. 
Y 
0.01, p = 0.939). 
CO-TWIN: MULTIVARIATE ANALYSIS 
Finally, we conducted a stepwise proportional haz- 
ards regression that began with all the variables previ- 
ously considered. Only two variables uniquely predicted 
the risk of GAD in the co-twin: total number of symp- 
toms (x’ = 18.60, p = 0.000) and comorbidity with 
bulimia nervosa (x’ = 4.33, p = 0.038). (The third vari- 
able entered into the stepwise regression, total num- 
ber of episodes, was accepted into the model but then 
rejected because itsp value, 0.184, exceeded 0.10.) Do- 
ing a median split, the relative risk for GAD in the co- 
twin of proband twins with 5 9 vs. > 9 endorsed 
symptoms was 1.72. The  relative risk tended to in- 
crease if the threshold for number of symptoms in- 
creased: 5 10 vs. > 10 - 1.68, 5 12 vs. > 12 - 1.89, < 
14 vs. > 14 - 2.52 and I 16 vs. > 16 - 5.46. The  
relative risk for GAD in the cotwins of proband 
twins with versus without a diagnosis of bulimia 
nervosa was 1.69. 
DISCUSSION 
We found that it was possible to relate clinical and 
etiologic heterogeneity in GAD. Individuals with a 
high familial vulnerability to GAD, as reflected by the 
risk for GAD in their co-twins, systematically differed 
in certain of their clinical characteristics from twins 
with a low familial vulnerability. 
The strongest unique predictor of risk of illness in 
relatives was the number of endorsed symptoms. In 
GAD, an individual’s familial vulnerability to illness is 
apparently indexed by the number of symptoms expe- 
rienced and reported. These results are in striking 
contrast to a parallel analysis in this same data set of 
major depression (Kendler et al., 1994) in which the 
number of endorsed symptoms was unrelated to the 
risk for depression in the co-twin. Unlike with major 
depression, our findings suggest that the validity of 
the GAD syndrome, from a familial perspective, might 
be increased if a larger number of symptoms were re- 
quired to meet diagnostic criteria. 
The other unique predictor of risk for GAD in rela- 
tives was lifetime comorbidity with bulimia. The same 
result occurred in our parallel analysis of major depres- 
sion in this sample (Kendler et al., 1994), suggesting that 
bulimia in women may reflect a high familial vulnerabil- 
ity to several inter-related psychiatric syndromes. 
Length of longest episode of GAD was unrelated to 
the risk for GAD in the co-twin. From a familial per- 
spective, a longer minimum duration of GAD does 
not appear to increase the validity of the diagnostic 
category. These results do not support the substantial 
prolongation of the minimal duration of a GAD epi- 
sode from one month in DSM-I11 to six months in 
DSM-111-R and DSM-TV. 
Number of episodes significantly predicted the risk 
for GAD in the co-twin, but when other factors were 
controlled for, this result lost significance. These re- 
sults suggest that recurrence in GAD is not as good an 
index of familial vulnerability to this illness as it is for 
major depression (Gershon et al., 1986; Bland et al., 
1986; Kendler et al., 1994). 
We were unable to find evidence that GAD present- 
ing largely with somatic versus psychic symptoms 
(Hoehn-Saric et al., 1989) differed in familial vulner- 
ability. Controlling for the total number of endorsed 
symptoms, the number of hypervigilant vs. auto- 
nomic hyperactivity items endorsed did not signifi- 
cantly relate to the risk for GAD in the co-twin. It 
may still be possible that in pairs of concordant twins, 
members resemble one another in their GAD symp- 
tom profiles. This question will be addressed in subse- 
quent analyses. 
Age at onset of GAD also was unrelated to the risk 
of illness in the co-twin. Early age at onset has been 
associated with increased familial vulnerability to ill- 
ness for several neuropsychiatric disorders including 
Alzheimer’s disease (Heston et al., 198 l), alcoholism 
(Goodwin, 1984) and, in most studies, affective illness 
(Weissman et al., 1984). If our finding is confirmed, it 
suggests that age a t  onset of GAD may be influenced 
primarily by non-familial factors, which could include 
environmental stressors. 
When using a one-month minimum duration of ill- 
ness, GAD is quite a common disorder in the general 
population (Breslau and Davis, 1985; Wells et al., 
1989; Robins and Regier, 1991; Kendler et al., 1992b). 
If the goal is to produce a GAD syndrome that is less 
common, our results suggest that, from a familial per- 
spective, it will be more valid to increase the minimum 
number of required symptoms than to increase the re- 
quired duration beyond the one month proposed in 
LIMITATIONS 
Our results should be interpreted in the context of 
three potential limitations. First, our results are rel- 
evant only for females. Although little is known about 
DSM-111. 
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gender differences in the familial influences on GAD, 
given the known differences in prevalence of anxiety 
disorder in men and women (Robins and Regier, 1991; 
Wells et al., 1989), it is possible that the familial vulner- 
ability to GAD may manifest differently across sexes. 
Second, as outlined above, the diagnostic criteria for 
GAD assessed in this study included most, but not all, 
of those included in the final version of DSM-111-R 
(American Psychiatric Association, 1987), the most 
significant change being a reduction in the minimum 
duration of illness from six to one month. We did not 
attempt analyses with “6-month” GAD, because of 
previous experience in this data set that this disorder 
was too rare to provide stable statistical estimates 
(Kendler et al., 1992b). 
Third, in this report, we related the clinical charac- 
teristics of GAD to the tendency for GAD to aggregate 
in families. We have previously shown in this sample 
that the familial aggregation of GAD can be best ex- 
plained as a result solely of genetic factors (Kahn et al., 
1986). Therefore, the indices of familial GAD found 
in this report probably reflect the genetic, and not just 
the fimilial, liability to GAD. While it would have 
been desirable to demonstrate this directly, the class of 
analyses reported here cannot currently be performed 
with the more appropriate sophisticated methods, in 
large part because of the problems of multi-dimen- 
sional integration (Neale et al., 1989; Kendler et al., 
1994). A more definitive resolution of the issues ad- 
dressed in this report must await the availability of 
such models. 
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